Melhem Solh
A5004066032- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Polyomavirus and related diseases
- Renal Transplantation Outcomes and Treatments
- Chronic Myeloid Leukemia Treatments
- Immune Cell Function and Interaction
- Multiple Myeloma Research and Treatments
- T-cell and B-cell Immunology
- Monoclonal and Polyclonal Antibodies Research
- Protein Degradation and Inhibitors
- Medical Imaging Techniques and Applications
- Synthesis and pharmacology of benzodiazepine derivatives
- Histone Deacetylase Inhibitors Research
- Lung Cancer Treatments and Mutations
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Transplantation: Methods and Outcomes
- Cytomegalovirus and herpesvirus research
- Childhood Cancer Survivors' Quality of Life
- HER2/EGFR in Cancer Research
- Eosinophilic Disorders and Syndromes
Northside Hospital
2016-2025
PharmaMar (Spain)
2023
Mayo Clinic in Florida
2023
Costa Rican Department of Social Security
2023
National Hospital for Neurology and Neurosurgery
2023
University College London
2023
BMT Group (United States)
2022
Moffitt Cancer Center
2017
Johns Hopkins Hospital
2017
Florida Hospital Cancer Institute
2012-2016
Purpose T-cell-replete HLA-haploidentical donor hematopoietic transplantation using post-transplant cyclophosphamide was originally described bone marrow (BM). With increasing use of mobilized peripheral blood (PB), we compared transplant outcomes after PB and BM transplants. Patients Methods A total 681 patients with hematologic malignancy who underwent in the United States between 2009 2014 received (n = 481) or 190) grafts. Cox regression models were built to examine differences by graft...
In patients undergoing allogeneic hematopoietic stem-cell transplantation (HSCT), a calcineurin inhibitor plus methotrexate has been standard prophylaxis against graft-versus-host disease (GVHD). A phase 2 study indicated the potential superiority of post-transplantation regimen cyclophosphamide, tacrolimus, and mycophenolate mofetil.
Abstract Multiple myeloma (MM) is a plasma cell malignancy expressing B maturation antigen (BCMA). Elranatamab, bispecific antibody, engages BCMA on MM and CD3 T cells. The MagnetisMM-1 trial evaluated its safety, pharmacokinetics efficacy. Primary endpoints, including the incidence of dose-limiting toxicities as well objective response rate (ORR) duration (DOR), were met. Secondary efficacy endpoints included progression-free survival (PFS) overall (OS). Eighty-eight patients with relapsed...
Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of
Outcomes of 475 consecutive patients undergoing first allogeneic transplantation for hematologic malignancy performed using T-replete HLA-haploidentical donors and post-transplantation cyclophosphamide (HIDT; n = 116) were compared with contemporaneous transplanted from 10 HLA allele-matched unrelated (MUDT; 178) or HLA-identical sibling (MRDT; 181). Uniform supportive care measures assessments used. Median follow-up was 45 months. HIDT more likely than MUDT to be black (44% versus 2%; P <...
The poor prognosis for patients with diffuse large B cell lymphoma (DLBCL) who relapse within 1 year of initial diagnosis after first-line rituximab-based chemo-immunotherapy has created controversy about the role autologous transplantation (HCT) in this setting. We compared HCT outcomes chemosensitive DLBCL between 2000 and 2011 2 cohorts based on time to from diagnosis. early rituximab failure (ERF) cohort consisted primary refractory disease or those first ERF was relapsing >1 (late [LRF]...
Abstract HLA-haploidentical hematopoietic cell transplantation (Haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a matched sibling (MSD) is still considered the optimal donor. Using Center for International Blood and Marrow Transplant Research database, we compared outcomes after Haplo-HCT vs MSD in patients with acute myeloid leukemia (AML) first complete remission (CR1). Data from 1205 adult CR1 AML (2008-2015) were analyzed. A total...
ADCT-402 (loncastuximab tesirine) is an antibody-drug conjugate comprising a CD19-targeting antibody and pyrrolobenzodiazepine dimers. A first-in-human study evaluated the safety preliminary clinical activity of loncastuximab tesirine in patients with B-cell non-Hodgkin lymphoma (NHL).A multicenter, phase I, dose-escalation dose-expansion enrolled ages ≥18 years relapsed/refractory (R/R) NHL. Patients received every 3 weeks at doses assigned by 3+3 design. Dose escalation was used to assess...
Highlights•Data-driven guidance is needed to help select haploidentical donors.•Presence of HLA-DR mismatch and HLA-DP nonpermissive improve survival.•Presence KIR R-L B/x with 2DS2 haplotype survival.•Avoidance parental donors CMV-negative for CMV-positive recipients improves survival.•KIR genotyping should be considered donor selection.AbstractThe use post-transplant cyclophosphamide (PTCy)-based (haplo) transplant increasing worldwide. However, because multiple potential haplo are usually...
Abstract Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF patients treated with allogeneic HCT (551 patients) and without (non-HCT) (1377 was analyzed Cox proportional hazards model. Survival analysis stratified by Dynamic International Prognostic Scoring System (DIPSS) revealed that first year of treatment arm assignment, due to upfront risk transplant-related...
Abstract The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes HCT approaches by donor adults with ALL in remission. primary objective was to compare overall survival (OS) among HCTs PTCy and HLA-matched sibling (MSD), 8/8 unrelated (MUD), 7 /8 HLA-MUD, or umbilical cord blood (UCB) HCT. Comparing MSD HCT,...
<h3>Importance</h3> Primary central nervous system lymphoma (PCNSL) requires induction and consolidation to achieve potential cure. High-dose therapy autologous hematopoietic cell transplant (AHCT) is an accepted effective strategy for PCNSL, but no consensus exists on the optimal conditioning regimens. <h3>Objective</h3> To assess outcomes in patients with PCNSL undergoing AHCT 3 most commonly used regimens: thiotepa/busulfan/cyclophosphamide (TBC), thiotepa/carmustine (TT-BCNU),...
Matched sibling donors (MSDs) are preferred for allogeneic hematopoietic cell transplantation (allo-HCT) in myelodysplastic syndrome even if they older. However, whether older MSDs or younger human leukocyte antigen-matched unrelated (MUDs) associated with better outcomes remains unclear.To investigate allo-HCT using MUDs would be improved disease-free survival and less relapse compared MSDs.This retrospective cohort study assessed data reported to the Center International Blood Marrow...
Abstract The overall survival (OS) has improved significantly in multiple myeloma (MM) over the last decade with use of proteasome inhibitor and immunomodulatory drug-based combinations, followed by high-dose melphalan autologous hematopoietic stem cell transplantation (auto-HSCT) subsequent maintenance therapies eligible newly diagnosed patients. However, clinical trials using auto-HSCT lenalidomide have shown an increased risk second primary malignancies (SPM), including hematological...
Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative treatment for myelofibrosis. However, optimal conditioning regimen either with reduced-intensity (RIC) or myeloablative (MAC) is not well known. Using Center International Blood and Marrow Transplant Research database, we identified adults aged ≥18 years myelofibrosis undergoing allo-HCT between 2008-2019 analyzed outcomes separately in RIC MAC cohorts based on regimens used. Among 872 eligible patients, 493...
Related human leukocyte antigen (HLA)-haploidentical bone marrow transplantation (BMT) with posttransplant cyclophosphamide may be curative for sickle cell disease. However, graft failure, severe graft-versus-host disease (GVHD), infections, and mortality remain a concern. We evaluated novel conditioning regimen followed by related HLA-haploidentical BMT in adults In phase 2, open-label, single-arm, multicenter study, 54 eligible participants from 19 U.S. centers were enrolled. Of these, 42...
Key Points The effect of donor age on survival is negated by the patient age. Survival did not differ between sibling and offspring transplantation.
Natural killer (NK) cell immunotherapy as a cancer treatment shows promise, but expanding NK cells consistently from small fraction (∼ 5%) of peripheral blood mononuclear (PBMCs) to therapeutic amounts remains challenging. Most current ex vivo expansion methods use co-culture with feeder (FC), their poses challenges for wide clinical application. We developed particle-based technology that uses plasma membrane particles (PM-particles) derived K562-mbIL15-41BBL FCs. These PM-particles induce...